Abstract
Introduction
Adherence to treatment in osteoporosis remains poor. The aim of this study was to evaluate the effects of an educational leaflet on adherence to medication and to assess the association between adherence and health-related quality of life (HRQOL).
Methods
A naturalistic, observational, multi-center, prospective study of 12 months’ follow-up was performed. Consecutive post-menopausal women aged 50 years to 86 years starting treatment with raloxifene according to daily practice were enrolled from 126 primary care offices in Spain. The women were assigned to two study groups. Group A received an educational leaflet with general information about osteoporosis; group B followed current practice. To assess adherence to medication and HRQOL, the Morisky test and the EuroQoL questionnaire were administered. A total of 745 post-menopausal women (group A, n=366; group B n=379), with a mean age of 62 years, were included.
Results
Most patients in both study groups showed high adherence to raloxifene at the 3-month visit: 56.3% vs 62.7% for groups A and B, respectively; this proportion at the 12-month visit was 47.4% (P=0.15) and 52.5% (P=0.02), respectively. At baseline, “pain/discomfort” was the dimension showing the highest percentage of women reporting problems: 86.4% vs 83.2% in groups A and B, respectively (P=0.22). HRQOL improved in both groups throughout the study, with an overall mean increment in the EuroQoL visual analog scale (EQ VAS) of 9.2 at 12 months (P<0.01). Correlations between adherence and HRQOL were weak. After receiving an educational leaflet, young post-menopausal women suffering osteoporosis did not show improvement in adherence to therapy. HRQOL improved at 12-month follow-up under treatment.
Conclusion
No consistent correlation between adherence and HRQOL was found.
Similar content being viewed by others
References
Osteoporosis prevention, diagnosis, and therapy (2001) JAMA 285:785–795
Looker AC, Orwoll ES, Johnston CC Jr, et al (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761–1768
Osteoporosis postmenopausica. Guía de práctica clinica (2003) Rev Clin Esp 203:496–506
Diaz CM, Carrasco de la Pena JL, Honorato PJ, et al (1997) Study of bone mineral density in lumbar spine and femoral neck in a Spanish population. Multicentre research project on osteoporosis. Osteoporos Int 7:59–64
Cook DJ, Guyatt GH, Adachi JD, et al (1999) Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. Osteoporos Int 10:207–213
Kado DM, Browner WS, Palermo L, et al (1999) Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:1215–1220
Ray NF, Chan JK, Thamer M, et al (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35
Greendale GA, Barrett-Connor E, Ingles S, et al (1995) Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc 43:955–961
Ettinger B, Black DM, Mitlak BH, et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645
Delmas PD, Ensrud KE, Adachi JD, et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617
Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123
Turbi C, Herrero-Beaumont G, Acebes JC, et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256
McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288:2868–2879
Haynes RB, McDonald HP, Garg AX (2002) Helping patients follow prescribed treatment: clinical applications. JAMA 288:2880–2883
Blalock SJ, Currey SS, DeVellis RF, et al (2000) Effects of educational materials concerning osteoporosis on women’s knowledge, beliefs, and behavior. Am J Health Promot 14:161–169
Blalock SJ, DeVellis BM, Patterson CC, et al (2002) Effects of an osteoporosis prevention program incorporating tailored educational materials. Am J Health Promot 16:146–156
Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74
Val JA, Amoros BG, Martinez VP, et al (1992) Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. Aten Primaria 10:767–770
Badia X, Roset M, Montserrat S, et al (1999) The Spanish version of EuroQol: a description and its applications. European quality of life scale. Med Clin 112 [Suppl 1]:79–85
Jamal SA, Ridout R, Chase C, et al (1999) Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study. J Bone Miner Res 14:2143–2149
Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074–1090
Tosteson AN, Grove MR, Hammond CS, et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216
Papaioannou A, Ioannidis G, Adachi JD, et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813
Badia X, Diez-Perez A, Alvarez-Sanz C, et al (2001) Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO. Qual Life Res 10:307–317
Badia X, Diez-Perez A, Lahoz R, et al (2004) The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis. Health Qual Life Outcomes 2:41
Cote I, Farris K, Feeny D (2003) Is adherence to drug treatment correlated with health-related quality of life? Qual Life Res 12:621–633
Billups SJ, Malone DC, Carter BL (2000) The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy 20:941–949
Holzemer WL, Corless IB, Nokes KM, et al (1999) Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 13:185–197
Campbell MK, Mollison J, Steen N, Grimshaw JM, Eccles M (2000) Analysis of cluster randomized trials in primary care: a practical approach. Fam Pract 17:192–196
Acknowledgments
We wish to thank all general practitioners participating in the OPTIMA study: Dr. Benilde Tejido Garca, Dr. Dolores Prados Cano, Dr. Jose Felix Paredes Monelos, Dr. Jose Vazquez Cacheiro, Dr. Ma Jose Veleiro Tenreiro, Dr. Cristina Iglesias Diaz, Dr. Manuel Alonso Diaz, Dr. Jose Ma Garcia Polon, Dr. Martin San Millan Honrado, Dr. Carmen Amez Revuelta, Dr. Joaquin Juan Dieguez, Dr. Miguel Angel Rodriguez Lois, Dr. Montserrat Latorre Casedas, Dr. Maria Cerrato Rodriguez, Dr. Jose Manuel Goimil Martinez, Dr. Julio Rica Jelusich, Dr. Jose Miguel De Barruetabeña Gutierrez, Dr. Manuel Pena Otero, Dr. Alberto Losada Martínez, Dr. Francisco Pazos, Dr. Eduardo Tamayo Aguirre, Dr. Pablo Ferreiro Alonso, Dr. Jose Felix Zuazagoitia Nabla, Dr. Ma Angeles Sanza Garcia, Dr. Jose A. Estevez Barrondo, Dr. Jose Toledo Martinez, Dr. Carmen Garces Romero, Dr. Laura Martinez Alonso, Dr. Jose A. Montiu Peman, Dr. Estela Rodrigo, Dr. Ma Dolores Garcia Benaite, Dr. Jaime Cortes, Dr. Jose Manuel Ballester, Dr. Antonio Serrano Olover, Dr. Montserrat Espuga Garcia, Dr. Rosa Freixedas Casaponsa, Dr. Joan Isidro Ortega, Dr. Rosa Segarra Granell, Dr. Ma Luisa Moro Esteban, Dr. Ma Pilar Paramo Abai, Dr. Antonia Alonso Fresneda, Dr. Merce Fuentas Pujol, Dr. Casimir Moneny Sanchez, Dr. Eliseo Castell Friguls, Dr. Josep Ma Sans I Escola, Dr. Javier Rodriguez Pascual, Dr. Margarita Cañizares Nuñez, Dr. Josep Sorribes Lopez, Dr. Emili Balague Portus, Dr. Narcis Gratacos, Dr. Joan Cartanya, Dr. Juan Antonio Contreras Torres, Dr. Carlos Almendro Padill, Dr. Amparo Garcia Royo, Dr. Rosario Gonzalez Cabeza, Dr. Vicente Gasull Molinera, Dr. Ma Luisa Altarriba Cano, Dr. Francisco Beneyto Castello, Dr. Luis Estal Andres, Dr. Rosa Albelda Vendrell, Dr. Eduardo Canto Rodriguez, Dr. Jesus Navas Cutanda, Dr. Francisco Anton Garcia, Dr. Emilia Hernanz Torres, Dr. Ramon Lopez Guillen, Dr. Francisco Martinez Aguilar, Dr. Alejandra Caturla Perez, Dr. Fatima Perez Martinez, Dr. Daniel Vicente Fuentes, Dr. Francisco Martinez Cruz, Dr. Jose Segura Palomares, Dr. Jose Rodriguez Fernandez, Dr. Vicente Laborda Reinon, Dr. Jose Antonio Perez Lopez, Dr. Sebastian Jose Perez Martinez, Dr. Jose Manuel Suarez Sanchez, Dr. Ma Isabel Moreno Moreno, Dr. Carlos Martin Perez, Dr. Jose Andres Lopez Del Hierro, Dr. Nicolas Garrido Redondo, Dr. Cristobal Rodriguez Vicioso, Dr. Salvador Gotor Maroto, Dr. Salvador Cardenas Viedma, Dr. David Molina Fernandez, Dr. Ernesto Dios Lopez, Dr. Gabriel Caro Ruiz, Dr. Juan Manuel Lopez Zajara, Dr. Santiago Lupiani Gimenez, Dr. Jesus Casado Recio, Dr. Antonio Maine Martinez, Dr. Isabel Ramirez Polo, Dr. Rodrigo Romero Bernal, Dr. Juan Luis Hinojosa Gallardo, Dr. Francisco Manzano Gomez, Dr. Miguel Garcia Leon, Dr. Antonio Ortega Cabezaz, Dr. Miguel Silva Cueto, Dr. Fernando Morales Fernandez, Dr. Rafael Nieto Cervera, Dr. Luis Villanueva Horh, Dr. Ildefonso Esteban Fonseca, Dr. Juan Antonio Martin Jimenez, Dr. Carlos Miranda Fernandez-Santos, Dr. Luis Vitores Montoya, Dr. Emerito Peramato Martin, Dr. J. Sanchez Acosta, Dr. Juan Ignacio Pintado Pico, Dr. Maria De La O Bueno Reyes, Dr. Antonio Ruiz Garcia, Dr. Ezequiel Arranz Martinez, Dr. Emilio Jose Delgado Hellin, Dr. Dolores Sanchez Sanchez, Dr. Feliciano Lopez Sanhcez, Dr. Pablo Romero Marquez, Dr. Ana Martinez Cabrera, Dr. Esther Moreno Gonzalez, Dr. Purificacion Martinez Vilariño, Dr. Ma Fatima Garcia Areces, Dr. Domingo Ly Pen, Dr. Ma Luisa Gomez Rabago, Dr. Ma Jose Alvarez Pasquin, Dr. Francisco Cirujano Pita, Dr. Ma Antonia Martinez Montero, Dr. Maria Davalos De Haro, Dr. Ma Luisa Sanchez Ludeña, Dr. Ma Luz Caballero Hijon. The study was financially supported by PENSA-Esteve S.A and conducted by HOR-Europe.
Author information
Authors and Affiliations
Consortia
Corresponding author
Appendix 1: Leaflet text on general information regarding menopause
Appendix 1: Leaflet text on general information regarding menopause
What is postmenopause? | ||
As the name suggests, postmenopause is the time of life after the menopause (the end of menstruation). Taking care of your health is particularly important at this time because the changes brought about by postmenopause can lead to health risks. | ||
What happens during postmenopause? | ||
Postmenopausal women produce less female hormones (oestrogen), which means they are at a considerably higher risk of suffering osteoporosis or bone fractures and may contract cardiovascular diseases. It is therefore important to have regular medical check-ups in order to help avoid these risks and so that you can continue living life to the full. | ||
Postmenopause is a danger to your bones | ||
During postmenopause, bone decalcification increases which leads to the onset of osteoporosis. This means that the amount of bone we have per unit volume decreases and our bones become more fragile and easier to break. Without the right care, postmenopausal women may lose up to 5% of their bone mass every year during this stage in their lives. Although osteoporosis usually begins during menopause, bones are actually fractured many years later. The first bones to break are the spine and wrists, followed several years later by the hips. Because this is a silent illness, the first symptom you note could be the first fracture, when it may already be too late. This means that prevention is vital. If you are already suffering osteoporosis you may need to take medication in order to slow down the bone loss. Your GP will be able to tell you what the best course of medication is for you. | ||
Are you at risk of osteoporosis or fractures? | ||
Answer the following questions to find out. | ||
1. Did you reach menopause before you were 40? | □YES | □NO |
2. Are you thin and small-boned? | □YES | □NO |
3. Do you have a family history of fractures? | □YES | □NO |
4. Is your lifestyle sedentary or lacking in exercise? | □YES | □NO |
5. Do you smoke and/or drink? | □YES | □NO |
6. Do you eat few foods rich in calcium (milk/cheese/yogurt)? | □YES | □NO |
The more ‘yes’ answers you have, the greater the risk of osteoporosis. See your GP. | ||
Look after your heart | ||
At this time of your life you are more likely to experience cardiovascular problems. This is because before the menopause your hormones protected you from harmful cholesterol. Now, because the oestrogen levels in your body are lower, hardening of the arteries, chest pains or a heart attack become more of a risk. | ||
Are you in danger of suffering heart disease? | ||
Answer the following questions to find out. | ||
1. Do you have a family history of heart disease? | □YES | □NO |
2. Do you have high cholesterol? | □YES | □NO |
3. Do you smoke and/or drink? | □YES | □NO |
4. Do you have a hectic lifestyle? | □YES | □NO |
5. Are you overweight? | □YES | □NO |
6. Are you diabetic? | □YES | □NO |
If your answer to any of these questions is ‘yes’, you are at more risk of heart disease. Keeping an eye on how much salt you eat, getting physical exercise and following your GP’s advice will all help to prevent heart disease at this time in your life. | ||
Protect your breasts and uterus | ||
After the menopause there is also a higher risk of breast cancer and cervical tumors. This is why regular medical check-ups are essential - they are the only way to protect yourself from possible risks. This is particularly true in the case of breast cancer which is the most common kind of cancer among women and causes no initial symptoms or pain. | ||
Do you have regular medical check-ups? | ||
□ NO If you don’t see your GP regularly, we advise you to do so. Your GP can give you advice on your diet so that you can stay healthy. | ||
□ YES Keep having check-ups in order to protect yourself from possible complications related to postmenopause. | ||
C for Calcium | ||
It is very important to have a healthy, balanced diet in order to help check the effects of the menopause, particularly osteoporosis. The first step to take is to increase your calcium intake. | ||
A diet that is rich in calcium is essential to help you prevent osteoporosis. | ||
It is also a good idea to consult your GP about possible additional preventative treatment, since calcium tablets are very often needed to supplement the diet. Remember also that skimmed dairy produce contains the same amount of calcium as full-fat products. | ||
Is your diet right for your bones at this new stage in your life? | ||
Fill in the questionnaire below to find out if you are eating the most suitable kind of food. | ||
1. Do you drink at least 2 or 3 glasses of milk a day? | □YES | □NO |
2. Do you eat yogurts, custards and so on at least 2 or 3 times a week? | □YES | □NO |
3. Do you eat cheese at least 2 or 3 times a week? | □YES | □NO |
4. Do you regularly eat other foods (blue fish, nuts, etc.)? | □YES | □NO |
If you have answered ‘NO’ to most of these questions you should be eating a more balanced diet in order to minimize the risk of osteoporosis. See your GP. | ||
If you have answered ‘YES’ to most of these questions your diet is suitable to prevent health risks such as osteoporosis. | ||
Your spine is pivotal | ||
A bit of physical exercise or the right sport will help you stay in shape and prevent and slow down osteoporosis and bone fractures, as well as making your heart strong. | ||
It is very important that the exercise you do does not bend or twist your spine too much, or expose you to possible falls. For instance, a half-hour brisk walk every day may be enough. | ||
There are several very appealing sports and activities that are particularly suited to this time of life and that will help to strengthen your bones and protect them from osteoporosis, such as walking, cycling, swimming and dancing. The activities that are most commonly linked to spinal fractures are those carried out at home or in the workplace. | ||
Are you aware of your posture in your day-to-day life? | ||
Answer the following questions to find out. | ||
1. Do you sit with your feet resting on the ground and your back and neck in a straight line? | □YES | □NO |
2. Do you sleep on your back or your side on a firm mattress and use a light pillow? | □YES | □NO |
3. When you pick something up off the floor, do your bend your hips and knees with your back straight and keep the object close to your body? | □YES | □NO |
If you have answered ‘NO’ to any of these questions you should correct your posture and look after your spine more. Try to keep your back straight whenever you bend down and when you move or push objects. | ||
Your GP can advise you | ||
Your GP knows most about any problems you may experience as a postmenopausal woman and is the only person who can tell you what treatment is best suited to you and your needs. | ||
In your case, your GP has chosen raloxifene (which is not a hormone) because it is ideal for preventing and treating osteoporosis, as well as for avoiding other possible health risks linked to postmenopause. | ||
In addition, raloxifene will not cause any blood loss or staining, increase your weight or cause tenderness in your breasts, and you will be at no greater risk of breast or cervical cancer. | ||
Follow your treatment exactly | ||
Unless you take your medication regularly, your treatment will be less effective. Bear in mind the following points: | ||
•Take one tablet a day. It doesn’t matter if you take it with food or not, but taking it at the same time every day will help you to remember it. | ||
•If you forget to take a tablet, take it as soon as you remember and continue the treatment as normal. If you are several hours late, wait until the following day to continue treatment. Nothing will happen if you miss one day. | ||
•Swallow the tablet whole with any kind of drink. | ||
•Try not to abandon treatment unless your GP tells you to. | ||
•If you have any questions, speak to your GP. |
Rights and permissions
About this article
Cite this article
Guilera, M., Fuentes, M., Grifols, M. et al. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 17, 664–671 (2006). https://doi.org/10.1007/s00198-005-0031-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-005-0031-8